Kymera climbs after expedited timeline for mid-stage eczema trial
Seeking Alpha ·
Kymera Therapeutics ( KYMR ) added ~10% in the premarket on Thursday after announcing an expedited timeline to share topline data from a mid-stage trial for KT-621, its experimental therapy for atopic dermatitis (eczema). The global Phase 2b trial, named BROADEN2, for KT-621 in
DYAX Investor Sentiment
Bullish (Long) 47% · Bearish (Short) 53%
543 participants
Related News
- PVH's Middle East exposure could cloud recovery through 2026 — BofA Securities
- JPMorgan Chase plans to expand Community Center program, doubling branches in low-income areas
- Stifel cuts Microsoft target, says Street FY27 gross margin estimates are too high
- SpaceX vs. Tesla: Which Will Grow More Over the Next 12 Months?
- Nasdaq reverses course in a volatile session and hands back Micron earnings gains
- JPMorganChase Doubles Down on Community Banking to Expand Affordable Access and Financial Health Education Through the American Dream Initiative